Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Starbucks Corp (SBUX) Price & Performance

Adaptive Biotechnologies CorpTrade
Starbucks CorpTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Starbucks Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Starbucks Corp trades at $108.4 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 30.1× Adaptive Biotechnologies Corp's market cap, and Starbucks Corp pays a 2.33% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTSBUX
Market Cap
$4.04B$121.59B
Sector
HealthConsumer Cyclical
52-Week High
$25.45$108.37
52-Week Low
$12.30$78.46
Enterprise Value
$4.10B$140.42B
Volume
7,493,833
Dividend Yield
2.33%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

Starbucks Corp

Starbucks (SBUX) trades at $108.03, up 3.23% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 guidance, though valuation remains elevated at a P/E of 61.65. Recent news highlights a successful turnaround strategy under CEO Brian Niccol, with traffic recovery and margin expansion driving optimism.

The outlook remains positive with analyst consensus pointing to $113.60 price target, though high valuation and execution risks require monitoring. Key opportunities include sustained traffic growth and cost efficiency initiatives, while risks involve premium pricing sensitivity and competitive pressures in the coffee retail space.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Starbucks Corp

Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.

Read more on SBUX